DRREDDY

The US FDA issued a Form 483 with five observations at

biologics manufacturing facility in Hyderabad following a September 4-12 pre-approval inspection. The company will address the issues within the stipulated timeline. This comes after Dr Reddy's announced a $50.5 million deal with Johnson & Johnson to acquire the Stugeron portfolio for 18 markets.